PT - JOURNAL ARTICLE AU - Hartman, Steven J. AU - Hibberd, Matthew C. AU - Mostafa, Ishita AU - Nahar, Naila N. AU - Islam, Md. Munirul AU - Zaman, Mahabub Uz AU - Huq, Sayeeda AU - Mahfuz, Mustafa AU - Islam, Md. Tazul AU - Mukherji, Kallol AU - Moghaddam, Vaha Akbary AU - Chen, Robert Y. AU - Province, Michael A. AU - Webber, Daniel M. AU - Henrissat, Suzanne AU - Henrissat, Bernard AU - Terrapon, Nicolas AU - Rodionov, Dmitry A. AU - Osterman, Andrei L. AU - Barratt, Michael J. AU - Ahmed, Tahmeed AU - Gordon, Jeffrey I. TI - A microbiome-directed therapeutic food for children recovering from severe acute malnutrition AID - 10.1101/2024.06.11.24307076 DP - 2024 Jan 01 TA - medRxiv PG - 2024.06.11.24307076 4099 - http://medrxiv.org/content/early/2024/06/13/2024.06.11.24307076.short 4100 - http://medrxiv.org/content/early/2024/06/13/2024.06.11.24307076.full AB - Severe acute malnutrition (SAM), defined anthropometrically as a weight-for-length z-score more than 3 standard deviations below the mean (WLZ<-3), affects 19 million children under 5-years-old worldwide. Complete anthropometric recovery after standard inventions is rare with children often left with moderate acute malnutrition (MAM; WLZ -2 to -3). Here we conduct a randomized controlled trial (RCT), involving 12-18-month-old Bangladeshi children from urban and rural sites, who after hospital-based treatment for SAM received a 3-month intervention with a microbiota-directed complementary food (MDCF-2) or a ready-to-use supplementary food (RUSF) as they transitioned to MAM. The rate of WLZ improvement was significantly greater with MDCF-2 than the more calorically-dense RUSF, as we observed in a previous RCT of Bangladeshi children with MAM without antecedent SAM. A correlated meta-analysis of aptamer-based measurements of 4,520 plasma proteins in this and the prior RCT revealed 215 proteins positively-associated with WLZ (prominently those involved in musculoskeletal and CNS development) and 44 negatively-associated proteins (related to immune activation), with a significant enrichment in levels of the positively WLZ-associated proteins in the MDCF-2 arm. Characterizing changes in 754 bacterial metagenome-assembled genomes in serially collected fecal samples disclosed the effects of acute rehabilitation for SAM on the microbiome, its transition as each child achieves a state of MAM, and how specific strains of Prevotella copri function at the intersection between MDCF-2 glycan metabolism and the rescue of growth faltering. These results provide a rationale for further testing the generalizability of the efficacy of MDCF and identify biomarkers for defining treatment responses.One Sentence Summary A microbiota-directed food that targets specific gut bacterial taxa promotes growth in Bangladeshi children recovering from severe acute malnutritionCompeting Interest StatementA.L.O. and D.A.R. are co-founders of Phenobiome Inc., a company pursuing development of computational tools for predictive phenotype profiling of microbial communities. A joint patent application between Washington University in St Louis and icddr,b has been filed, entitled Synbiotic combination of selected strains of P. copri and dietary glycans to treat malnutrition, with J.I.G., M.C.H., D.M.W., M.J.B. and T.A. listed as co-inventors (PCT/US2023/018738). The authors are committed to the principle of Global Access; patented technologies will be made available and accessible at an affordable price to those in need throughout the world.Clinical TrialNCT04015986Funding StatementThis work was supported by the Bill & Melinda Gates Foundation (OPP1196579 and INV-016367 to Washington University School of Medicine in St. Louis, INV-008846 to icddr,b), the National Institutes of Health (DK30292) and the Washington University-Centene Personalized Medicine Initiative.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical Review Committee at the icddr,b gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors and metagenomic sequencing data will be available in the European Nucleotide Archive under accession PRJEB63587. https://gitlab.com/sjhartman/post-sam-mam-code-repository https://github.com/rodionovdima/PhenotypePredictor